Literature DB >> 11389733

Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum.

V K Gopal1, S H Francis, J D Corbin.   

Abstract

To date, relative cellular levels of cGMP and cGMP-binding proteins have not been considered important in the regulation of smooth muscle or any other tissue. In rabbit penile corpus cavernosum, intracellular cGMP was determined to be 18 +/- 4 nM, whereas the cGMP-binding sites of types Ialpha and Ibeta cGMP-dependent protein kinase (PKG) and cGMP-binding cGMP-specific phosphodiesterase (PDE5) were 58 +/- 14 nM and 188 +/- 6 nM, respectively, as estimated by two different methods for each protein. Thus, total cGMP-binding sites (246 nM) greatly exceed total cGMP. Given this excess of cGMP-binding sites and the high affinities of PKG and PDE5 for cGMP, it is likely that a large portion of intracellular cGMP is associated with these proteins, which could provide a dynamic reservoir for cGMP. Phosphorylation of PDE5 by PKG is known to increase the affinity of PDE5 allosteric sites for cGMP, suggesting the potential for regulation of a reservoir of cGMP bound to this protein. Enhanced binding of cGMP by phosphorylated PDE5 could reduce the amount of cGMP available for activation of PKG, contributing to feedback inhibition of smooth muscle relaxation or other processes. This introduces a new concept for cyclic nucleotide signaling.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11389733     DOI: 10.1046/j.1432-1327.2001.02233.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  15 in total

1.  cGMP-dependent protein kinase protects cGMP from hydrolysis by phosphodiesterase-5.

Authors:  Jun Kotera; Kennard A Grimes; Jackie D Corbin; Sharron H Francis
Journal:  Biochem J       Date:  2003-06-01       Impact factor: 3.857

Review 2.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

3.  Allosteric-site and catalytic-site ligand effects on PDE5 functions are associated with distinct changes in physical form of the enzyme.

Authors:  Jackie D Corbin; Roya Zoraghi; Sharron H Francis
Journal:  Cell Signal       Date:  2009-08-06       Impact factor: 4.315

Review 4.  Effects of cyclic nucleotide phosphodiesterases (PDEs) on mitochondrial skeletal muscle functions.

Authors:  Liliane Tetsi; Anne-Laure Charles; Stéphanie Paradis; Anne Lejay; Samy Talha; Bernard Geny; Claire Lugnier
Journal:  Cell Mol Life Sci       Date:  2016-12-30       Impact factor: 9.261

5.  Contractile agonists attenuate cGMP levels by stimulating phosphorylation of cGMP-specific PDE5; an effect mediated by RhoA/PKC-dependent inhibition of protein phosphatase 1.

Authors:  K S Murthy
Journal:  Br J Pharmacol       Date:  2008-01-21       Impact factor: 8.739

6.  The effect of DA-8159 on corpus cavernosal smooth muscle relaxation and penile erection in diabetic rabbits.

Authors:  Kyung Koo Kang; Seul Min Choi; Gook Jun Ahn; Jong Won Kwon; Won Bae Kim
Journal:  Urol Res       Date:  2004-03-13

7.  Melatonin inhibits nitric oxide signaling by increasing PDE5 phosphorylation in coronary arteries.

Authors:  Praveen Shukla; Chengwen Sun; Stephen T O'Rourke
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-10-19       Impact factor: 4.733

8.  Interactions between cGMP- and cAMP-pathways are involved in the regulation of penile smooth muscle tone.

Authors:  Stefan Uckert; Petter Hedlund; Eginhard Waldkirch; Michael Sohn; Udo Jonas; Karl-Erik Andersson; Christian G Stief
Journal:  World J Urol       Date:  2004-03-26       Impact factor: 4.226

9.  Sidenafil pre-treatment promotes decompression sickness in rats.

Authors:  Jean-Eric Blatteau; Alf O Brubakk; Emmanuel Gempp; Olivier Castagna; Jean-Jacques Risso; Nicolas Vallée
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

Review 10.  Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists.

Authors:  Sharron H Francis; Jackie D Corbin
Journal:  Curr Urol Rep       Date:  2003-12       Impact factor: 2.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.